GHK-Cu
Copper tripeptide (Gly-His-Lys-Cu)
GHK-Cu is a naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine + copper) first found in human plasma — and one of the most researched peptides in skin science. It's studied for collagen production, skin regeneration, wound healing and hair, and it comes in two very different forms: topical (cosmetic) and injectable (research). This guide covers how GHK-Cu works, what the research actually shows, topical vs injectable use, dosing references, safety and legal status.
GHK-Cu quick facts
| Reported research dosing | 1mg-5mg |
| Route | Subq |
| Cycle length | - |
| Frequency | 1-2x Daily Am and PM · 5 On 2 Off or Daily |
| Half-life | Variable (topical bioavailability varies) |
| Forms | Injectable, Oral, Topical |
| Evidence level | In-vitro + topical human |
Skin, hair and repair. Watch copper balance if you run it long-term.
How GHK-Cu works
GHK-Cu is essentially a signal for tissue remodeling. It carries copper — a required cofactor for the enzymes that build and remodel the extracellular matrix — and at very low (nanomolar) concentrations it stimulates the synthesis of collagen, elastin and glycosaminoglycans, while also balancing the matrix-metalloproteinases and their inhibitors (TIMP-1/TIMP-2) that break tissue down. Beyond that, GHK acts as an epigenetic regulator: research shows it influences the expression of hundreds of genes tied to wound repair, antioxidant defense and inflammation control.
What the research shows & benefits
Skin & collagen. This is GHK-Cu's strongest evidence. Lab studies show it can raise collagen production substantially, and in a human trial comparing topical GHK-Cu to vitamin C and retinoic acid, GHK-Cu increased collagen in about 70% of volunteers — outperforming both.
Wound healing. Across animal models (rats, mice, rabbits, pigs) GHK-Cu accelerates wound closure, improves skin-graft integration, and increases angiogenesis and antioxidant enzyme levels.
Hair. GHK is used to support hair-follicle health and improve hair-transplant outcomes; results vary and the hair evidence is less mature than the skin evidence.
Topical vs injectable GHK-Cu
GHK-Cu is unusual in that it's both a cosmetic ingredient and a research injectable. Topically, it's widely used in serums and creams (commonly 1–4% concentrations) for skin firmness, texture and fine lines — the best-supported, lowest-risk way to use it. Injectable GHK-Cu is used in research and some clinical settings for more systemic skin/tissue goals, but it carries the usual research-compound cautions and should only be handled by qualified professionals. For most people interested in skin, the topical route is where the human evidence is strongest.
GHK-Cu dosing (research reference)
Topical: the literature commonly references 1–4% GHK-Cu concentrations, with skin-texture improvements often reported within 2–4 weeks and collagen/firmness changes over 8–12 weeks of consistent use. Injectable: research references a roughly 1–3 mg/day subcutaneous range, often starting lower and titrating up, reconstituted with bacteriostatic water — the calculator above converts a research amount into syringe units. Injectable use should only be set by a qualified provider. This summarizes existing references for education only, not as a recommendation for human use.
Safety & side effects
Topical GHK-Cu is generally very well tolerated, with irritation being the main occasional issue. Injectable GHK-Cu has far less human safety data; because copper is biologically active, dose matters, and quality/purity in the research market varies — a Certificate of Analysis and professional oversight are important. As always, this is educational information, not medical advice.
Related compounds & stacking
GHK-Cu is a common partner to the healing peptides — it's the collagen/skin arm of blends like GLOW and KLOW, which pair it with BPC-157 and TB-500 for a combined skin-and-recovery approach.
Legal & regulatory status
Topical GHK-Cu is a legal, widely-sold cosmetic ingredient. Injectable GHK-Cu is not FDA-approved and is offered as a research compound (research use only); its compounding status, like other peptides, is subject to ongoing FDA review. Follow the laws that apply to you.
Where to get GHK-Cu
GHK-Cu is sold in 3 forms. They are not interchangeable — the dose and the route differ, so pick the one this page describes unless you know why you want another.
GHK-Cu reconstitution calculator
Research reconstitution calculator
Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for GHK-Cu
Graded by what exists behind each claim.
✅ Clinically validated
- The topical human evidence is real and it is the best-supported claim on this page. Controlled trials of copper-peptide creams show measurable improvements in skin density, fine lines and wound healing — which is why GHK-Cu is a mainstream cosmetic ingredient rather than a research chemical.
- There are no human trials of injected GHK-Cu for any systemic endpoint.
📊 Correlative data
- Plasma GHK-Cu falls sharply with age — roughly 200 ng/mL at 20 down to about 80 by 60 — which is an observation about human biology rather than about supplementation, and it is the origin of the whole systemic-use idea.
- Injected use is reported for hair, skin and connective tissue. It reliably causes a local reaction at the injection site, which is the most consistent thing in the anecdotal record.
🧪 Theoretical / extrapolated
- A copper-carrying tripeptide that modulates gene expression broadly — published transcriptomic work shows it shifts expression of a very large number of genes toward a repair-associated pattern.
- The copper is the mechanism and also the limit. It works by delivering copper into cells, so systemic dosing has a ceiling that topical use does not: copper is tightly regulated in the body for good reason, and more signaling is not straightforwardly better.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What GHK-Cu actually does
The molecule is three residues — Gly-His-Lys — and everything that matters about it is the histidine. The copper(II) ion is held by a three-nitrogen donor set: the free N-terminal amine of glycine, the deprotonated nitrogen of the first peptide bond, and the imidazole nitrogen of the histidine side chain. That geometry is close to square planar and it produces a complex with an unusually high affinity for Cu(II) — strong enough to compete for copper in serum, weak enough to hand it over. The computational study of that binding is Alshammari 2020, and the reason to spell out the coordination chemistry is that Gly-His-Lys without copper is a different pharmacology from Gly-His-Lys with it, and vendors sell both under names that differ by two letters.
The step nobody explains is how the copper gets out, and it was measured directly. Ufnalska 2021 followed the reduction of Cu(II)-GHK by glutathione and found it proceeds through intermediate Cu(II)-thiolate species; the paper's own description of the complex is a handy chelate for biological Cu(II) reduction. Glutathione sits at millimolar concentration inside cells and micromolar outside. So the complex is stable in plasma and is reduced where glutathione is — inside the cell — and Cu(I) is released there. GHK-Cu is a copper delivery vehicle with a redox trigger, and the trigger is the intracellular/extracellular glutathione gradient.
That single fact reorganizes the whole page. Copper is a cofactor for lysyl oxidase, the enzyme that cross-links collagen and elastin; for superoxide dismutase 1; for cytochrome c oxidase; and for dopamine beta-hydroxylase. A large part of what is attributed to "the peptide" is what a bioavailable copper ion does when it reaches an apo-enzyme that was waiting for one.
The peptide half is not nothing, and the cleanest evidence for it is enzymatic. Simeon 2000 reported that the tripeptide-copper complex stimulates matrix metalloproteinase production in fibroblasts — which is remodeling, not simply synthesis. That distinction is the one this compound is most often described wrongly: GHK-Cu does not just lay down collagen, it upregulates the machinery that breaks old matrix down as well, and coordinated turnover is what tissue repair actually is. Gruchlik 2012 adds the inflammatory arm, comparing GHK and Gly-Gly-His and their copper complexes on TNF-alpha-dependent IL-6 secretion, and Pyo 2007 the hair-follicle arm in vitro.
The broad gene-expression claims — that GHK shifts the expression of thousands of genes toward a younger profile — come from Pickart 2018 and Pickart 2015, and they are database analyses of connectivity-map signatures rather than experiments in tissue. Worth reading, worth not mistaking for a measured outcome.
Cell, rodent, human — and where it stops
Step one, the chemistry: solid. Coordination geometry Alshammari 2020, glutathione-dependent reduction and copper release Ufnalska 2021, antioxidant and antiglycation behavior of the complex Tosto 2023. This part is real chemistry with real numbers.
Step two, in cells. MMP stimulation in fibroblasts Simeon 2000, IL-6 modulation Gruchlik 2012, hair follicle effects Pyo 2007. Consistent, and all of it applied directly to cells in a dish at concentrations chosen by the experimenter.
Step three, in rodents — and there is one systemic study that matters far more than the topical literature for the injectable product on this page. Deng 2023 exposed C57BL/6 mice to cigarette smoke and treated them with GHK-Cu at 0.2 and 2 mg/kg. Skeletal muscle dysfunction was rescued: grip strength improved, muscle mass loss was reduced, fiber cross-sectional area increased, and the effect was SIRT1-dependent. This is a systemically dosed, dose-ranged animal study with a functional endpoint and a named pathway — the strongest single piece of evidence that injected GHK-Cu does something outside the skin.
Step three-and-a-half, and this is the one human number on the page. The same paper measured plasma GHK in nine people with COPD against controls: 70.27 ng/mL versus 133.0 ng/mL, p=0.009 Deng 2023. That is a real human deficiency signal in a real disease, and it is the empirical version of the older claim that plasma GHK falls with age Pickart 2012.
Step four, in humans as a treatment: essentially nothing for the injectable. The human evidence for GHK-Cu is cosmetic and topical — creams, small studies, dermatology endpoints. There is no published trial of subcutaneous GHK-Cu in people for muscle, for tendon, or for anything else.
The obstacles, named one at a time. (1) A nine-person plasma comparison is an association; it does not establish that low GHK causes anything or that raising it helps. (2) Topical and injected are different products — the skin is a barrier and a target at once, and dermal delivery bypasses the systemic copper question entirely. (3) The mouse doses, 0.2 and 2 mg/kg, bracket a range far above the 1–5 mg totals people inject; the allometry has never been worked. (4) The gene-expression claims are computational.
What would have to be true, and how you would know it was not
Three predictions, and the first is unique to this compound in the whole Vault: it is the only one where the deliberate, repeated administration of a trace metal is the mechanism.
1. Serum copper and ceruloplasmin should be watched, and this is the prediction that cuts against the product. GHK-Cu is a copper carrier that unloads inside cells Ufnalska 2021. Milligram doses of the complex, given daily for months, deliver copper on a schedule nobody has modeled. Draw copper and ceruloplasmin at baseline and at 12 weeks. Ceruloplasmin carries most of the circulating copper and is also an acute-phase reactant, so read it beside hs-CRP or it will mislead you.
2. Zinc should be measured at the same time, because copper and zinc compete. Copper and zinc share intestinal transport and regulate each other through metallothionein induction; chronic copper loading is a recognized way to depress zinc status, and low zinc is quietly relevant to almost everything this compound is taken for — healing, hair, immune function, testosterone. Serum zinc, or better RBC zinc, at both ends. A rising copper with a falling zinc is the specific pattern that means stop.
3. If the muscle mechanism transfers, grip strength is the endpoint the animal data actually moved. Deng 2023 used grip strength and fiber cross-sectional area, not appearance and not a subjective score. A hand dynamometer costs almost nothing, and grip strength measured at baseline and 12 weeks with training held constant is the cheapest available test of whether the SIRT1 muscle result means anything in a person.
What nobody has tested yet
Four things nobody has tested, and the first is the one that should worry a daily user most.
Nobody has measured copper status in a person injecting GHK-Cu long term. Not once. The compound's own mechanism is copper delivery Ufnalska 2021; serum copper, ceruloplasmin and RBC zinc are ordinary tests; and the intersection is empty. Ten people with before-and-after panels would produce the first real safety data this compound has for systemic use.
Nobody has compared GHK against GHK-Cu head to head in a person. Both are sold. If the chemistry above is right, the copper-free peptide should be substantially weaker for anything involving lysyl oxidase or SOD1 and roughly equal for anything mediated by the peptide sequence itself. That is a clean two-arm design and it would tell buyers which product they should be buying.
Nobody has repeated the COPD plasma finding at scale. Nine subjects Deng 2023. A few hundred, stratified by age, smoking and muscle mass, would establish whether plasma GHK is a usable biomarker of anything — and a compound with a biomarker is a different proposition from a compound without one.
Nobody has tested the glutathione dependence in vivo. The release step requires glutathione Ufnalska 2021, so the mechanism predicts that a glutathione-depleted tissue — a smoker's lung, an aging muscle, a person on chronic acetaminophen — unloads copper differently from a healthy one. Nobody has manipulated glutathione status and re-measured the effect, in any species.
GHK-Cu — its own safety story, not its class's
The class block above is written for repair peptides. This one has a metal in it, and that changes the safety story completely.
The dose that matters is the copper dose, and nobody calculates it. Copper is roughly 20% of the molecular weight of the complex, so a 5 mg dose of GHK-Cu carries on the order of 1 mg of copper — comparable to a full day's dietary intake, delivered past the gut, where the body's main copper regulatory checkpoint sits. Intestinal absorption is how copper homeostasis is controlled; injection bypasses it. That is a mechanistic statement, not an observed harm, and it is the single most important thing on this page that no vendor mentions.
Two conditions where this is not a theoretical issue. Wilson disease is a genetic failure of copper excretion, and any condition with cholestasis impairs the biliary route that copper leaves the body by. In both, added parenteral copper accumulates. These are uncommon, they are testable with ceruloplasmin and a liver panel, and they are the reason the marker list above is not optional.
The redox argument runs both ways, which is why the "antioxidant peptide" framing is incomplete. The complex has measured antioxidant and antiglycation behavior Tosto 2023, and free copper is a Fenton-active metal that generates hydroxyl radicals. Chelated copper is protective; released copper that finds no apo-enzyme is not. The whole safety argument depends on the release step being matched to demand, and no one has shown that it is.
The topical and injectable products are not interchangeable. Dermal use keeps the copper largely where it is applied and has decades of cosmetic history behind it. The systemic route has one dose-ranged rodent study Deng 2023 and no human trial. Reading the safety of the second from the history of the first is the most common error made with this compound.
Sources read for this page
- Ufnalska I, et al. Intermediate Cu(II)-Thiolate Species in the Reduction of Cu(II)GHK by Glutathione: A Handy Chelate for Biological Cu(II) Reduction. Inorganic Chemistry 2021 · PMID 34781677
- Deng M, et al. Glycyl-L-histidyl-L-lysine-Cu2+ rescues cigarette smoking-induced skeletal muscle dysfunction via a sirtuin 1-dependent pathway. Journal of Cachexia, Sarcopenia and Muscle 2023 · PMID 36905132
- Pickart L, et al. The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health. Oxidative Medicine and Cellular Longevity 2012 · PMID 22666519
GHK-Cu — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- The copper is the active ingredient and also the constraint. Copper is an essential trace mineral with a genuine upper limit, and these deliver it directly.
- Topically over a small area this is not a systemic concern. Large surface areas, high concentrations, or injecting it are a different proposition — the same molecule at a different exposure.
What has actually been reported
- Topical use is well tolerated; irritation and temporary blue-green staining are the common complaints, both cosmetic.
How to reduce the risk
Same mechanism as the prediction.
- Match the exposure to the goal. A face-sized area of a topical is a different proposition from full-body use or injection. Most of the cosmetic benefit is local, so there is rarely a reason to escalate to systemic exposure for a skin outcome.
- Keep it away from direct vitamin C in the same layer. Copper and ascorbic acid deactivate each other — this wastes both rather than harming you, but it is the most common way people get nothing from an expensive product. Vitamin C in the morning, copper at night.
- Don't stack multiple copper products at once. A copper serum, a copper shampoo and a copper body lotion are three doses of the same mineral, and the ceiling is on the mineral, not on the product.
- If you are injecting it or covering large areas long-term, serum copper and ceruloplasmin are the two markers that would actually show accumulation.
What it does to your bloodwork
A fact about the assay.
- If you are using this at scale or injecting it, serum copper and ceruloplasmin are the markers that would show accumulation.
Don't run this if
- Wilson's disease or any condition of copper handling — the mechanism is delivering the exact thing you cannot clear.
The honest unknown
- Cumulative copper load from long-term high-surface-area topical use has not been characterized.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Close to the tissue, and consistency beats the clock
A brief exposure starts a process that runs for days, so the hour you dose is a minor variable — missing days is the one that costs you. Where the target is local, dosing near the site is worth more than any timing choice.
From half-life and route, not a dosing trial.
GHK-Cu — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What GHK-Cu moves on your bloodwork
Expected direction, not a measured one.
- Copper, Serum — ↑ expected to rise
Only relevant at systemic doses — topical use does not meaningfully raise serum copper.
What to do: Not routinely needed. It matters if you are injecting it regularly or already have a copper-handling condition. - Ceruloplasmin — ◆ worth watching
The copper-carrying protein, and the one that tells you whether copper is bound and safe or free and reactive.
What to do: Read with serum copper, never alone. - Zinc, Plasma — ↓ expected to fall
Copper and zinc compete for absorption. Sustained copper loading predicts falling zinc, which then shows up as immune and taste changes that get blamed on something else.
What to do: If you are running copper systemically for months, check zinc.
Everything on this page, in an order
This one is free and stays free. What Skool adds is the rest of the shelf — 278 compounds and 371 supplements with the protocol, the stack order and the bloodwork to run beside it.
Join Skool — $10/mo →Bloodwork to run alongside GHK-Cu
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| Copper, Serum | It IS a copper peptide. Sustained use is a real copper-load question |
| Ceruloplasmin | The transport protein — read with copper or neither means much |
| Comprehensive Metabolic Panel (CMP) | Liver, which handles copper excretion |
| hs-CRP (High-Sensitivity C-Reactive Protein) | The inflammation and repair claim, measured |
The Heavy Metals & Mineral Balance panel covers these in one order — 7 markers, $270.90 with the discount applied.
Check results you already have → · All 103 markers A–Z
GHK-Cu — frequently asked questions
What is GHK-Cu?
GHK-Cu is a copper-binding tripeptide found naturally in human plasma, researched for collagen production, skin regeneration, wound healing and hair. It comes in topical (cosmetic) and injectable (research) forms.
How does GHK-Cu work?
It delivers copper needed for tissue-remodeling enzymes and stimulates collagen, elastin and glycosaminoglycan synthesis, while acting as an epigenetic regulator of genes tied to repair, antioxidant defense and inflammation.
Is topical or injectable GHK-Cu better?
For skin, topical GHK-Cu has the strongest human evidence and the lowest risk, and is a legal cosmetic ingredient. Injectable GHK-Cu is a research compound with less human safety data and should only be handled by qualified professionals.
How is GHK-Cu dosed?
Topical references commonly cite 1–4% concentrations; injectable research references roughly 1–3 mg/day subcutaneously, titrated and reconstituted with bacteriostatic water (see the calculator above). This is educational, not dosing advice.
Does GHK-Cu really boost collagen?
Research is supportive: lab studies show substantial collagen increases, and a human trial found topical GHK-Cu raised collagen in about 70% of volunteers, outperforming vitamin C and retinoic acid.
Is GHK-Cu FDA-approved?
Topical GHK-Cu is a legal cosmetic ingredient. Injectable GHK-Cu is not FDA-approved and is sold as a research compound, with compounding status under ongoing review.
References & further reading
- GHK peptide as a modulator of skin-regeneration pathways (PMC review)
- Skin-regenerative and anti-cancer actions of copper peptides (Cosmetics, MDPI)
GHK-Cu inside a finished plan
One arm of 2 Protocol Blueprints, free to read in full.
What GHK-Cu is used for
GHK-Cu appears under 2 goals in the goal router.
Related Healing & Recovery compounds
Where this goes next
GHK-Cu is the angiogenesis arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.